Literature DB >> 31974566

Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.

Eudocia Q Lee1,2, Michael Weller3, Joohee Sul4, Stephen J Bagley5, Solmaz Sahebjam6, Martin van den Bent7, Manmeet Ahluwalia8, Jian L Campian9, Evanthia Galanis10, Mark R Gilbert11, Matthias Holdhoff12, Glenn J Lesser13, Frank S Lieberman14, Minesh P Mehta15, Marta Penas-Prado11, Karisa C Schreck12, Roy E Strowd13, Michael A Vogelbaum6, Tobias Walbert16, Susan M Chang17, L Burt Nabors18, Stuart Grossman12, David A Reardon1,2, Patrick Y Wen1,2.   

Abstract

Building on an initiative to enhance clinical trial participation involving the Society for Neuro-Oncology, the Response Assessment in Neuro-Oncology Working Group, patient advocacy groups, clinical trial cooperative groups, and other partners, we evaluate the impact of eligibility criteria and trial conduct on neuro-oncology clinical trial participation. Clinical trials often carry forward eligibility criteria from prior studies that may be overly restrictive and unnecessary and needlessly limit patient accrual. Inclusion and exclusion criteria should be evaluated based on the goals and design of the study and whether they impact patient safety and/or treatment efficacy. In addition, we evaluate clinical trial conduct as a barrier to accrual and discuss strategies to minimize such barriers for neuro-oncology trials.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  clinical trials; eligibility; exclusion criteria; inclusion criteria; primary brain tumor

Mesh:

Year:  2020        PMID: 31974566      PMCID: PMC7229255          DOI: 10.1093/neuonc/noaa015

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  57 in total

1.  Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.

Authors:  Derin B Keskin; Annabelle J Anandappa; Jing Sun; Itay Tirosh; Nathan D Mathewson; Shuqiang Li; Giacomo Oliveira; Anita Giobbie-Hurder; Kristen Felt; Evisa Gjini; Sachet A Shukla; Zhuting Hu; Letitia Li; Phuong M Le; Rosa L Allesøe; Alyssa R Richman; Monika S Kowalczyk; Sara Abdelrahman; Jack E Geduldig; Sarah Charbonneau; Kristine Pelton; J Bryan Iorgulescu; Liudmila Elagina; Wandi Zhang; Oriol Olive; Christine McCluskey; Lars R Olsen; Jonathan Stevens; William J Lane; Andres M Salazar; Heather Daley; Patrick Y Wen; E Antonio Chiocca; Maegan Harden; Niall J Lennon; Stacey Gabriel; Gad Getz; Eric S Lander; Aviv Regev; Jerome Ritz; Donna Neuberg; Scott J Rodig; Keith L Ligon; Mario L Suvà; Kai W Wucherpfennig; Nir Hacohen; Edward F Fritsch; Kenneth J Livak; Patrick A Ott; Catherine J Wu; David A Reardon
Journal:  Nature       Date:  2018-12-19       Impact factor: 49.962

2.  Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.

Authors:  James R Perry; Normand Laperriere; Christopher J O'Callaghan; Alba A Brandes; Johan Menten; Claire Phillips; Michael Fay; Ryo Nishikawa; J Gregory Cairncross; Wilson Roa; David Osoba; John P Rossiter; Arjun Sahgal; Hal Hirte; Florence Laigle-Donadey; Enrico Franceschi; Olivier Chinot; Vassilis Golfinopoulos; Laura Fariselli; Antje Wick; Loic Feuvret; Michael Back; Michael Tills; Chad Winch; Brigitta G Baumert; Wolfgang Wick; Keyue Ding; Warren P Mason
Journal:  N Engl J Med       Date:  2017-03-16       Impact factor: 91.245

3.  Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.

Authors:  Manfred Westphal; Seppo Ylä-Herttuala; John Martin; Peter Warnke; Philippe Menei; David Eckland; Judith Kinley; Richard Kay; Zvi Ram
Journal:  Lancet Oncol       Date:  2013-07-12       Impact factor: 41.316

4.  Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.

Authors:  Troy Z Horvat; Nelly G Adel; Thu-Oanh Dang; Parisa Momtaz; Michael A Postow; Margaret K Callahan; Richard D Carvajal; Mark A Dickson; Sandra P D'Angelo; Kaitlin M Woo; Katherine S Panageas; Jedd D Wolchok; Paul B Chapman
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

5.  cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".

Authors:  Daniel J Brat; Kenneth Aldape; Howard Colman; Eric C Holland; David N Louis; Robert B Jenkins; B K Kleinschmidt-DeMasters; Arie Perry; Guido Reifenberger; Roger Stupp; Andreas von Deimling; Michael Weller
Journal:  Acta Neuropathol       Date:  2018-09-26       Impact factor: 17.088

6.  Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.

Authors:  Edward S Kim; Suanna S Bruinooge; Samantha Roberts; Gwynn Ison; Nancy U Lin; Lia Gore; Thomas S Uldrick; Stuart M Lichtman; Nancy Roach; Julia A Beaver; Rajeshwari Sridhara; Paul J Hesketh; Andrea M Denicoff; Elizabeth Garrett-Mayer; Eric Rubin; Pratik Multani; Tatiana M Prowell; Caroline Schenkel; Marina Kozak; Jeff Allen; Ellen Sigal; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544

Review 7.  Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

8.  Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas.

Authors:  Won Jin Ho; Mark Yarchoan; Alex Hopkins; Ranee Mehra; Stuart Grossman; Hyunseok Kang
Journal:  J Immunother Cancer       Date:  2018-08-31       Impact factor: 12.469

9.  Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.

Authors:  Adam Diehl; Mark Yarchoan; Alex Hopkins; Elizabeth Jaffee; Stuart A Grossman
Journal:  Oncotarget       Date:  2017-12-14

10.  H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis.

Authors:  Bette K Kleinschmidt-DeMasters; Jean M Mulcahy Levy
Journal:  Clin Neuropathol       Date:  2018 Mar/Apr       Impact factor: 1.368

View more
  14 in total

Review 1.  Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors:  Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

Review 2.  Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Adult Medulloblastoma Workshop.

Authors:  Marta Penas-Prado; Brett J Theeler; Brittany Cordeiro; Ira J Dunkel; Peter Hau; Anita Mahajan; Giles W Robinson; Nicole Willmarth; Orwa Aboud; Kenneth Aldape; John A Butman; Amar Gajjar; William Kelly; Ganesh Rao; Margarita Raygada; Christine Siegel; Carlos G Romo; Terri S Armstrong; Mark R Gilbert
Journal:  Neurooncol Adv       Date:  2020-08-17

3.  The trial effect in patients with glioblastoma: effect of clinical trial enrollment on overall survival.

Authors:  Kaitlyn F Melnick; Patricia Miller; Ethan Carmichael; Kyle McGrath; Ashley Ghiaseddin; David D Tran; Maryam Rahman
Journal:  J Neurooncol       Date:  2022-07-15       Impact factor: 4.506

Review 4.  Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.

Authors:  Stephen J Bagley; Shawn Kothari; Rifaquat Rahman; Eudocia Q Lee; Gavin P Dunn; Evanthia Galanis; Susan M Chang; Louis Burt Nabors; Manmeet S Ahluwalia; Roger Stupp; Minesh P Mehta; David A Reardon; Stuart A Grossman; Erik P Sulman; John H Sampson; Simon Khagi; Michael Weller; Timothy F Cloughesy; Patrick Y Wen; Mustafa Khasraw
Journal:  Clin Cancer Res       Date:  2022-02-15       Impact factor: 13.801

5.  Disparities in patient enrollment on glioblastoma clinical trials.

Authors:  Yang Liu; Andrea Wasilewski; Nimish A Mohile
Journal:  CNS Oncol       Date:  2020-06-30

6.  The effects of releasing early results from ongoing clinical trials.

Authors:  Steffen Ventz; Sergio Bacallado; Rifaquat Rahman; Sara Tolaney; Jonathan D Schoenfeld; Brian M Alexander; Lorenzo Trippa
Journal:  Nat Commun       Date:  2021-02-05       Impact factor: 14.919

7.  Primary central nervous system lymphoma: a narrative review of ongoing clinical trials and goals for future studies.

Authors:  Lauren R Schaff; Prakash Ambady; Nancy D Doolittle; Christian Grommes
Journal:  Ann Lymphoma       Date:  2021-03

8.  Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?

Authors:  Erlend Skaga; Marthe Andrea Skretteberg; Tom Børge Johannesen; Petter Brandal; Einar O Vik-Mo; Eirik Helseth; Iver A Langmoen
Journal:  Neurooncol Adv       Date:  2021-02-26

9.  World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology.

Authors:  Erik P Sulman; David D Eisenstat
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

Review 10.  Clinical Trial Considerations in Neuro-oncology.

Authors:  Eudocia Q Lee
Journal:  Curr Treat Options Oncol       Date:  2021-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.